Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Atezolizumab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week

Candonilimab

Ming Shi, MD

To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Atezolizumab plus bevacizumab is the first-line treatent for patients with advanced hepatocellular carcinoma. However, the second-line treatment is absent for patients who progressed on atezolizumab plus bevacizumab. Candonilimab is a humanized bisspecific monoclonal antibody against PD-1/ CTLA-4 IgG1. Candonilimab plus lenvatinib showed strong anti-tumor effect, with objective response of 44%. This single-arm, prospective, phase 2 trial is to explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Candonilimab Plus Bevacizumab as Second-line Treatment for Patients With Advanced Hepatocellular Carcinoma Who Progressed on Atezolizumab Plus Bevacizumab: a Single Arm, Phase 2 Trial

DCR （Disease Control Rate） include complete response, partial response and stable Disease per RECIST 1.1

OS is the length of time from the date of randomization until death from any cause.

PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression or death due to any cause.

Objective response rate (complete response+partial response) per RECIST 1.1

Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report.

The blood specimen and needle biopsy specimen would be collected

Shi Ming

Proffessor

Atezolizumab plus bevacizumab is the first-line treatent for patients with advanced hepatocellular carcinoma. However, the second-line treatment is absent for patients who progressed on atezolizumab plus bevacizumab. Candonilimab is a humanized bisspecific monoclonal antibody against PD-1/CTLA-4 IgG1. Candonilimab plus lenvatinib showed strong anti-tumor effect, with objective response of 44%. This single-arm, prospective, phase 2 trial is to explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T	NCT05760599	Hepatocellular ...	Candonilimab Bevacizumab	18 Years - 75 Years	Sun Yat-sen University
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T	NCT05886257	Hepatocellular ...	Candonilimab Bevacizumab	18 Years - 75 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for candonilimab plus bevacizumab